PhaseRx Inc
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder program… Read more
PhaseRx Inc (PZRXQ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2017: 8.545x
Based on the latest financial reports, PhaseRx Inc (PZRXQ) has a cash flow conversion efficiency ratio of 8.545x as of September 2017.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.57 Million) by net assets ($-301.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PhaseRx Inc - Cash Flow Conversion Efficiency Trend (2014–2016)
This chart illustrates how PhaseRx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PhaseRx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PhaseRx Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ACTIVEX
BE:A4T
|
N/A |
|
Tristar Wellness
PINK:TWSI
|
0.009x |
|
WATER RES GRP
BE:WXV
|
N/A |
|
Alveen
PA:MLALV
|
N/A |
|
Arete Industries Inc
PINK:ARET
|
0.029x |
|
Imagin Medical Inc
PINK:IMEXF
|
-0.001x |
|
Optigis S.A.
WAR:OPI
|
N/A |
|
Finseta Plc
LSE:FIN
|
0.128x |
Annual Cash Flow Conversion Efficiency for PhaseRx Inc (2014–2016)
The table below shows the annual cash flow conversion efficiency of PhaseRx Inc from 2014 to 2016.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2016-12-31 | $9.30 Million | $-9.81 Million | -1.055x | -962.74% |
| 2015-12-31 | $-48.89 Million | $-5.98 Million | 0.122x | +4.52% |
| 2014-12-31 | $-41.54 Million | $-4.86 Million | 0.117x | -- |